» Articles » PMID: 28064215

Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies

Overview
Journal In Vivo
Specialty Oncology
Date 2017 Jan 9
PMID 28064215
Citations 168
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease (CKD) is a long-term condition in which the kidneys do not work correctly. It has a high prevalence and represents a serious hazard to human health and estimated to affects hundreds of millions of people. Diabetes and hypertension are the two principal causes of CKD. The progression of CKD is characterized by the loss of renal cells and their replacement by extracellular matrix (ECM), independently of the associated disease. Thus, one of the consequences of CKD is glomerulosclerosis and tubulointerstitial fibrosis caused by an imbalance between excessive synthesis and reduced breakdown of the ECM. There are many molecules and cells that are associated with progression of renal fibrosis e.g. angiotensin II (Ang II). Therefore, in order to understand the biopathology of renal fibrosis and for the evaluation of new treatments, the use of animal models is crucial such as: surgical, chemical and physical models, spontaneous models, genetic models and in vitro models. However, there are currently no effective treatments for preventing the progression of renal fibrosis. Therefore it is essential to improve our knowledge of the cellular and molecular mechanisms of the progress of renal fibrosis in order to achieve a reversion/elimination of renal fibrosis.

Citing Articles

The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.

Agur T, Steinmetz T, Goldman S, Zingerman B, Bielopolski D, Nesher E Cardiovasc Diabetol. 2025; 24(1):97.

PMID: 40022102 PMC: 11871758. DOI: 10.1186/s12933-025-02643-6.


The role of M1/M2 macrophage polarization in the pathogenesis of obesity-related kidney disease and related pathologies.

Dousdampanis P, Aggeletopoulou I, Mouzaki A Front Immunol. 2025; 15:1534823.

PMID: 39867890 PMC: 11758166. DOI: 10.3389/fimmu.2024.1534823.


Gum Resin Mitigates Renal Toxicity: Role of TNF-α, Interleukins, TGF-β, and Lipid Peroxidation.

Eltahir H, Shalkami A, Shehata A, Almikhlafi M, Aldhafiri A, Alalawi A Life (Basel). 2025; 14(12.

PMID: 39768376 PMC: 11676428. DOI: 10.3390/life14121669.


Apocynin and Hyperbaric Oxygen Therapy Improve Renal Function and Structure in an Animal Model of CKD.

Vukovic A, Karanovic D, Mihailovic-Stanojevic N, Miloradovic Z, Brkic P, Zivotic M Biomedicines. 2025; 12(12.

PMID: 39767695 PMC: 11673868. DOI: 10.3390/biomedicines12122788.


Personalized Antifibrotic Therapy in CKD Progression.

Delrue C, Eisenga M, Delanghe J, Speeckaert M J Pers Med. 2024; 14(12).

PMID: 39728054 PMC: 11678888. DOI: 10.3390/jpm14121141.


References
1.
Gagliardini E, Benigni A . Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev. 2005; 17(1-2):89-96. DOI: 10.1016/j.cytogfr.2005.09.005. View

2.
Griffin K, Picken M, Churchill M, Churchill P, Bidani A . Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol. 2000; 11(3):497-506. DOI: 10.1681/ASN.V113497. View

3.
Shimamura T, Morrison A . A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol. 1975; 79(1):95-106. PMC: 1913032. View

4.
Rodriguez-Pena A, Prieto M, Duwel A, Rivas J, Eleno N, Perez-Barriocanal F . Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant. 2001; 16 Suppl 1:34-9. DOI: 10.1093/ndt/16.suppl_1.34. View

5.
Klahr S, Morrissey J . Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002; 283(5):F861-75. DOI: 10.1152/ajprenal.00362.2001. View